These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19996274)

  • 1. Natural product derivative Bis(4-fluorobenzyl)trisulfide inhibits tumor growth by modification of beta-tubulin at Cys 12 and suppression of microtubule dynamics.
    Xu W; Xi B; Wu J; An H; Zhu J; Abassi Y; Feinstein SC; Gaylord M; Geng B; Yan H; Fan W; Sui M; Wang X; Xu X
    Mol Cancer Ther; 2009 Dec; 8(12):3318-30. PubMed ID: 19996274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diallyl trisulfide suppresses the proliferation and induces apoptosis of human colon cancer cells through oxidative modification of beta-tubulin.
    Hosono T; Fukao T; Ogihara J; Ito Y; Shiba H; Seki T; Ariga T
    J Biol Chem; 2005 Dec; 280(50):41487-93. PubMed ID: 16219763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
    Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
    Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
    Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-APCAs, the Novel Microtubule Targeting Agents Active Against Distinct Cancer Cell Lines.
    Boichuk S; Galembikova A; Bikinieva F; Dunaev P; Aukhadieva A; Syuzov K; Zykova S; Igidov N; Ksenofontov A; Bocharov P
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33503939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity.
    Qin M; Peng S; Liu N; Hu M; He Y; Li G; Chen H; He Y; Chen A; Wang X; Liu M; Chen Y; Yi Z
    J Pharmacol Exp Ther; 2015 Dec; 355(3):473-83. PubMed ID: 26377911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
    Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
    Pan H; Gu L; Sun S; Chen Z; Zhou H; Zeng S; Jiang H
    Drug Metab Dispos; 2013 May; 41(5):1082-93. PubMed ID: 23439662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
    Meng F; Cai X; Duan J; Matteucci MG; Hart CP
    Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
    Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
    Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Furanylazaindoles: potent anticancer agents in vitro and in vivo.
    Lee HY; Pan SL; Su MC; Liu YM; Kuo CC; Chang YT; Wu JS; Nien CY; Mehndiratta S; Chang CY; Wu SY; Lai MJ; Chang JY; Liou JP
    J Med Chem; 2013 Oct; 56(20):8008-18. PubMed ID: 24106982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.
    Chen YL; Lin SZ; Chang JY; Cheng YL; Tsai NM; Chen SP; Chang WL; Harn HJ
    Biochem Pharmacol; 2006 Jul; 72(3):308-19. PubMed ID: 16782069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine.
    Rathinasamy K; Jindal B; Asthana J; Singh P; Balaji PV; Panda D
    BMC Cancer; 2010 May; 10():213. PubMed ID: 20482847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel synthetic 1,3-phenyl bis-thiourea compound targets microtubule polymerization to cause cancer cell death.
    Shing JC; Choi JW; Chapman R; Schroeder MA; Sarkaria JN; Fauq A; Bram RJ
    Cancer Biol Ther; 2014 Jul; 15(7):895-905. PubMed ID: 24755487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells.
    Leoni LM; Hamel E; Genini D; Shih H; Carrera CJ; Cottam HB; Carson DA
    J Natl Cancer Inst; 2000 Feb; 92(3):217-24. PubMed ID: 10655438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.